Mepolizumab and reslizumab improve asthma control by binding to

Both Mepolizumab and reslizumab bind to interleukin-5 (IL-5), a key cytokine responsible for the differentiation, maturation, and activation of human eosinophils. Both antibodies bind to IL-5 and prevents binding to the interleukin 5 receptor alpha subunit, on the surface of eosinophil white blood cells. When these antibodies bind to IL-5, they stimulates B cell growth and increases immunoglobulin secretion, and this reduces the survival of eosinophils. Eosinophils, along with basophils and mast cells, are important mediators of allergic responses and severe asthmas.

Interleukin-5 (IL-5). IL-5 is responsible for the recruitment and maturation of eosinophil. Eosinophils on the other hand are majorly involved in the inflammatory response in asthma - characterised by narrowing of the airways. Mepolizumab and reslizumab are, therefore, anti-IL-5